Oric Pharmaceuticals Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027
Oric Pharmaceuticals reported Phase 1b results for enozertinib, showing 84% systemic and 70% intracranial response rates. The drug was well tolerated. The company plans a global Phase 3 trial, Redwood-1, in 2027, aiming to enroll 360 patients. According to the company, the trial will have dual primary endpoints of ORR and PFS.
How this was made
The 30-second read
Why it matters
The data could catalyze a price rally, but investors should monitor enrollment and safety signals in the upcoming trial.
Market read
First disclosure of promising trial data for a small‑cap biotech, likely to move the stock.
What to watch
Potential competition from other EGFR inhibitors and regulatory timelines.
Background
Oric filed an 8‑K reporting its Phase 1b enozertinib data and future Phase 3 plans.
Ticker impact
Oric Pharmaceuticals disclosed Phase 1b data showing 84% systemic ORR and 70% intracranial ORR for enozertinib, and announced a Phase 3 trial for 2027.
upward pressure as investors price in the high response rates and upcoming Phase 3 trial.
Phase 1b data with high ORR is material for a biotech; market typically reacts positively to such efficacy signals.
Market effects
May boost sentiment for other EGFR‑targeted oncology firms.
Limited to US biotech sector.
Modest, primarily relevant to investors tracking early‑stage cancer therapeutics.
Counterpoint
Phase 1b success does not guarantee Phase 3 outcomes; risk of later‑stage failure remains.
Key entities
- companyOric Pharmaceuticals
US‑listed biotech developing enozertinib for brain metastases.
